Apimeds Pharmaceuticals US, Inc (APUS) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Hopewell, NJ, 미국. 현재 CEO는 Youngjik Cho.
APUS 을(를) 보유 IPO 날짜 2025-05-09, 2 명의 정규직 직원, 에 상장 American Stock Excha, 시가총액 $2.36M.
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.
